Welcome to our dedicated page for Bicara Therapeutics news (Ticker: BCAX), a resource for investors and traders seeking the latest updates and insights on Bicara Therapeutics stock.
Bicara Therapeutics Inc. (NASDAQ: BCAX) is a clinical-stage biopharmaceutical company whose news flow centers on the development of its lead bifunctional antibody, ficerafusp alfa, for solid tumors. Company announcements frequently highlight progress in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), particularly HPV-negative disease, and provide updates on related clinical trials and regulatory interactions.
Recent news has included updates on the pivotal Phase 2/3 FORTIFI-HN01 trial of ficerafusp alfa in combination with pembrolizumab in first-line HPV-negative R/M HNSCC, preliminary and expanded Phase 1/1b cohort data, and the selection of dosing strategies intended to inform the pivotal study. Bicara has also reported that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in a defined subset of R/M HNSCC patients, and has used press releases to discuss how clinical data supported this designation.
In addition to clinical milestones, BCAX news items cover quarterly financial results, research and development spending, and cash and investment balances, reflecting the company’s status as a clinical-stage public issuer. Bicara also issues releases about participation in major medical and investor conferences, such as oncology congresses and healthcare investment events, where it presents clinical data or engages with the investment community.
Investors and observers following BCAX news can expect updates on FORTIFI-HN01 enrollment and interim analyses, data readouts from Phase 1/1b expansion cohorts in head and neck cancer and metastatic colorectal cancer, regulatory designations and guidance, and broader corporate developments. This news page aggregates those disclosures to help readers track the evolving clinical and corporate narrative around ficerafusp alfa and Bicara’s broader solid tumor strategy.
Bicara Therapeutics (Nasdaq: BCAX) awarded an inducement non-qualified stock option on March 2, 2026 to a new employee for 115,000 shares at an exercise price of $17.59, equal to the Nasdaq closing price that day.
The award vests 25% after one year, then in 12 equal quarterly installments, was granted under Bicara’s 2026 Inducement Plan (adopted January 2026) and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Bicara Therapeutics (Nasdaq: BCAX) closed an oversubscribed underwritten public offering on Feb 26, 2026, selling 8,581,250 shares and offering pre-funded warrants for 2,200,000 shares.
The underwriters fully exercised a 1,406,250-share option. Public prices were $16.00 per share and $15.9999 per pre-funded warrant, generating approximately $172.5 million gross proceeds before fees. Bicara plans to use net proceeds for regulatory filing and potential U.S. commercial launch of ficerafusp alfa, development in 1L R/M HPV-negative HNSCC, manufacturing, indication expansion signal-finding, and general corporate purposes.
Bicara Therapeutics (Nasdaq: BCAX) priced an underwritten public offering of 7,175,000 common shares at $16.00 per share and 2,200,000 pre-funded warrants at $15.9999 each, for gross proceeds of approximately $150 million. Closing is expected on or about February 26, 2026.
The company granted a 30-day underwriter option for 1,406,250 additional shares. Net proceeds will fund regulatory and commercial preparation for ficerafusp alfa, development in 1L R/M HPV-negative HNSCC, manufacturing, indication expansion signal-finding, and general corporate purposes.
Bicara Therapeutics (Nasdaq: BCAX) commenced an underwritten public offering of $150.0 million of common stock on February 24, 2026, with a 30‑day underwriter option to purchase up to an additional $22.5 million.
Proceeds are intended to fund the U.S. regulatory filing and potential commercial launch of ficerafusp alfa, accelerate development in 1L R/M HPV‑negative HNSCC, cover manufacturing costs, support indication expansion work, and for general corporate purposes. The offering is subject to market conditions and will be made from an effective Form S‑3 shelf registration.
Bicara Therapeutics (Nasdaq: BCAX) said company leadership will attend multiple investor conferences in early March 2026, with live fireside chats and webcasts scheduled. Ryan Cohlhepp, Pharm.D., President and COO, will present at TD Cowen (Mar 2) and Barclays (Mar 10) and attend Jefferies Biotech on the Beach (Mar 10-11).
Live webcasts and archived replays will be available via the company’s Investor Relations Events and Presentations page.
Bicara Therapeutics (Nasdaq: BCAX) presented Phase 1b data showing 2000mg ficerafusp alfa Q2W plus pembrolizumab produced a 48% confirmed ORR, 26% CR rate and 77% of responders with ≥80% tumor shrinkage (n=27; data snapshot Dec 16, 2025).
Results show sustained TGF-β inhibition and support development of a loading plus every‑three‑week maintenance regimen; a conference call is scheduled for Feb 20, 2026 at 8:30 a.m. ET.
Bicara Therapeutics (Nasdaq: BCAX) announced on February 5, 2026 that it granted inducement awards under its 2026 Inducement Plan to two new employees.
The company granted non-qualified stock options to purchase 158,900 shares at an exercise price of $16.76 per share (closing price on February 2, 2026). Awards vest 25% after one year then quarterly over three years and were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).
Bicara Therapeutics (NASDAQ: BCAX) selected 1500 mg weekly ficerafusp alfa (with pembrolizumab) as the optimal Phase 3 dose for the FORTIFI-HN01 pivotal trial in 1L HPV-negative R/M HNSCC.
The company expects substantial enrollment by end-2026 to enable an interim analysis in mid-2027 supporting a potential accelerated filing. Bicara also plans multiple expansion-cohort readouts in 2026, including Phase 1b data on 2000 mg every-other-week dosing in Q1 2026 and mCRC cohort results in H2 2026. Management will present at the J.P. Morgan Healthcare Conference on Jan 12, 2026.
Bicara Therapeutics (Nasdaq: BCAX) announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT.
A live webcast will be accessible via the company’s Investor Relations website under Events and Presentations, and a replay will be archived and available after the event.
Bicara Therapeutics (Nasdaq: BCAX) presented preliminary Phase 1b expansion data for ficerafusp alfa 750mg QW plus pembrolizumab in 1L HPV-negative R/M HNSCC on Dec 6, 2025.
Key metrics: 57% confirmed overall response rate, 10% complete responses, and 29% of responders with ≥80% tumor shrinkage at preliminary follow-up. Biomarker comparisons show 1500mg yields greater intratumoral TGF-β inhibition, higher immune activation, and deeper responses (median depth 82% vs 63%). Company expects to declare the pivotal FORTIFI-HN01 optimal dose in Q1 2026.